Oxford BioDynamics presented study data regarding its proprietary Episwitch platform at the Diabetes Asia 2017 Conference in Malaysia.
Type II diabetes mellitus (TD2) is a growing health issue in Asia. Between 2016 and 2011, prevalence of T2D in Malaysia increased by 31%.
Prior to developing T2D, patients progress through a pre-diabetes stage. Studies have shown that clinical intervention at the pre-diabetes stage can halt progression to full T2D.
In this study, 270 patients were categorised into four groups dependent on their TD2 status (healthy, prediabetes stage, treatment-naive and diabetes with treatment).
The study showed that after six months only 4% of patients with diabetes regressed to the healthy group whilst 44% of participants in the pre-diabetes stage regressed to the healthy group. Using epigenetic biomarkers, the Companys Episwitch platform could identify individuals in the prediabetes stage, the period where TD2 can be prevented.
Dr Alexandre Akoulitchev, Chief Scientific Officer of Oxford BioDynamics, commented: "This study demonstrates that there is considerable clinical utility in using our EpiSwitch technology to identify those at the pre-diabetic phase, and could be a powerful tool in tackling the overall increasing prevalence of diabetes.
Oxford BioDynamics is a clinical stage biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture for use within the pharmaceutical and biotechnology industry.